BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

NGR-hTNF: Phase II started

MolMed began the open-label, Italian Phase II NGR018 trial to evaluate 0.8 µg/m 2 IV NGR-hTNF every 4 weeks alone and in combination with pegylated liposomal doxorubicin in100 patients. ...

Read the full 129 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >